PTC THERAPEUTICS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.7B | $806.8M | $937.8M | $698.8M | $538.6M |
| Operating income | $866.9M | -$302.6M | -$439.5M | -$447.4M | -$374.4M |
| Operating expenses | $863.7M | $1.1B | $1.4B | $1.1B | $913.0M |
| Cash from operations | $711.2M | -$107.7M | -$158.4M | -$356.7M | -$251.3M |
| Capital expenditure | $8.9M | $6.5M | $28.4M | $32.0M | $28.2M |
| Free cash flow | $702.3M | -$114.2M | -$186.9M | -$388.7M | -$279.5M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $2.9B | $1.7B | $1.9B | $1.7B | $1.9B |
| Total liabilities | $3.1B | $2.8B | $2.7B | $2.1B | $1.9B |
Shares outstanding 8.3M · Free float 74.8%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.